Goal 3: Advance Translational Research

To facilitate innovation and accelerate research translation, knowledge dissemination, and implementation science that enhances public health.

Goal 3: Advance Translational Research

To expand the NHLBI emphasis on lymphatic research

The critical challenge is to acknowledge the central circulatory role of the lymphatic system and its requisite ability to provide integration of the circulation with the immune system. The NHLBI is challenged to provide programs, resources and education to stimulate and encourage increasing research into the function and the dysfunction of the lymphatics in human health and disease

Submitted by (@rockson)

Voting

5 net votes
12 up votes
7 down votes
Active

Goal 3: Advance Translational Research

Challenges for future clinical trials in COPD

There are two broad issues that any future clinical trials in COPD need to seriously consider, that of the challenges of timely and efficient subject recruitment and the need to increase the participation of low to middle income countries that experience a disproportionate burden of COPD in evidence generation. My specific suggestions are as follows: 1) Address the optimal medical management of multiple physical and psychological ...more »

Submitted by (@nhlbiforumadministrator)

Voting

2 net votes
2 up votes
0 down votes
Active

Goal 3: Advance Translational Research

Why are CHD Mortality Rates Much Higher in United States Than in Japan or Mediterranean Countries?

There remain very substantial unexplained international geographic variations in the incidence of CHD. Japan, for example, and some of the Mediterranean countries have CHD incidence rates for both men and women that are 1/3-1/4 of those in the United States.

Submitted by (@kullerl)

Voting

-8 net votes
10 up votes
18 down votes
Active

Goal 3: Advance Translational Research

What strategies improve implementation of COPD therapy, palliation, and dyspnea management

Chronic obstructive pulmonary disease (COPD) affects over 12-24 million individuals in the U.S. where it is responsible for ~ 800,000 hospitalizations per year, and recently became America’s 3rd leading cause of death. The lag between clinical practice and treatment options described by efficacy studies to improve the quality of life, functional status, and survival in patients with COPD make it ideal for efforts in patient-centered ...more »

Submitted by (@richard.mularski)

Voting

20 net votes
29 up votes
9 down votes
Active

Goal 3: Advance Translational Research

Tools to facilitate availability and safe use of innovative blood products and their analogs

Novel blood products are being developed based on innovative science (e.g., ex vivo manufactured RBC and platelets, and platelet and plasma derived hemostatic products). However, there is a significant lag in the development of appropriate tools and model systems, which poses a challenge when evaluating such products for regulatory approval.

Submitted by (@chintamani.atreya)

Voting

12 net votes
17 up votes
5 down votes
Active

Goal 3: Advance Translational Research

Current State of Regenerative Medicine: Moving Stem Cell Research from Animals into Humans for Clinical Trials

Realizing the developmental and therapeutic potential of pluripotent human embryonic stem cell (hESC) derivatives has been hindered by the inefficiency and instability of generating clinically-relevant functional cells from pluripotent cells through conventional uncontrollable and incomplete multi-lineage differentiation.

Submitted by (@xuejunparsons)

Voting

-21 net votes
13 up votes
34 down votes
Active

Goal 3: Advance Translational Research

Developing adherence research to reduce unnecessary mobility/mortality/cost

From Cochrane Review NOV 20 2014 RB Haynes “It is uncertain how medicine adherence can consistently be improved so that the full health benefits of medicines can be realized. We need more advanced methods for researching ways to improve medicine adherence, including better interventions, better ways of measuring adherence, and studies that include sufficient patients to draw conclusions on clinically important effects.” ...more »

Submitted by (@nhlbiforumadministrator)

Voting

5 net votes
7 up votes
2 down votes
Active